PENTA Foundation
39
5
10
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
3 terminated/withdrawn out of 39 trials
87.0%
+0.4% vs industry average
15%
6 trials in Phase 3/4
25%
5 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (39)
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Role: collaborator
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life
Role: collaborator
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
Role: collaborator
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
Role: collaborator
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.
Role: lead
Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance
Role: lead
Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
Role: lead
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children
Role: lead
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
Role: lead
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
Role: collaborator
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Role: collaborator
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
Role: collaborator
Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth
Role: collaborator
ODYSSEY (PENTA 20)
Role: lead
Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV
Role: lead
Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.
Role: lead
Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms
Role: lead
Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection
Role: lead
Monitoring COVID-19 Vaccination Response in Fragile Populations
Role: collaborator
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Role: collaborator